As the most widely used low molecular weight heparin (LMWH) globally, Enoxaparin Sodium dominates the anticoagulant market, with its demand and supply shaped by distinct geo-specific factors—from regulatory standards and clinical preferences to production hub advantages. With a global market size projected to reach $57.62 billion by 20313, Enoxaparin Sodium has become a cornerstone of thrombosis prevention and treatment, while its global accessibility hinges on manufacturers’ ability to adapt to regional requirements. Jiulong, leveraging China’s position as the world’s leading LMWH production base, delivers geo-adapted Enoxaparin Sodium solutions, combining strict multi-regional compliance, tailored formulations, and stable supply to serve partners across mature and emerging markets.

　　As a key low molecular weight heparin (LMWH) for thrombosis prevention and treatment, Dalteparin Sodium boasts a geo-diversified global market, shaped by regional clinical preferences, regulatory standards, and production capacity distribution. With the global LMWH market projected to grow at a CAGR of 9.1% from 2025 to 20343, China has emerged as the world’s critical green production hub—accounting for 28.5% of global Dalteparin Sodium capacity by 20251. Jiulong, leveraging this strategic advantage, delivers geo-adapted Dalteparin Sodium solutions, tailoring formulations to regional clinical needs while ensuring strict compliance and cost-efficiency, positioning itself as a trusted global partner for anticoagulant supply.

　　Geo-specific clinical indications define the demand landscape for Dalteparin Sodium, and Jiulong’s portfolio is engineered to meet these diverse needs. In Western Europe—the second-largest LMWH market3—Dalteparin Sodium is primarily used for extended treatment of cancer-related venous thromboembolism (VTE), as recommended in clinical guidelines2, so we offer high-purity pre-filled syringes (5000 IU, 7500 IU) optimized for long-term dosing. In North America, where postoperative thromboprophylaxis dominates demand2, our Dalteparin Sodium formulations align with USP standards for once-daily administration. In China, amid accelerating domestic substitution1, we provide cost-effective vial formulations (2500 IU, 5000 IU) compliant with national Volume-Based Procurement (VBP) policies, catering to growing primary care demand.

　　Regulatory compliance and price adaptability are core to Jiulong’s Dalteparin Sodium global strategy, addressing geo-specific market barriers. To access the EU market, we hold EU EDQM CEP certification and align production with Ph. Eur. monographs, ensuring traceability and impurity control—critical for competing in a market dominated by branded products1. For the U.S., we maintain an activated FDA DMF filing, supporting supply for both surgical and pediatric VTE treatment2. In China, our Dalteparin Sodium meets the latest Pharmacopoeia standards and is included in the national medical insurance catalog, while our green production processes reduce costs by 22%, enabling competitive pricing without compromising quality— a key advantage amid global raw material volatility1.

　　Jiulong’s competitive edge stems from integrating China’s green production hub advantage with robust supply chain resilience. Backed by China’s 2025 Dalteparin Sodium production capacity of 185 tons1, our annual capacity accounts for 12% of domestic output, ensuring stable supply for global markets. We adopt green enzymatic hydrolysis technology, reducing three-waste emissions by 40% compared to traditional processes—aligning with global environmental goals and EU sustainability regulations. Our full-chain control, from high-quality porcine raw material sourcing to finished product packaging, ensures Dalteparin Sodium purity exceeds 99.5%, with consistent molecular weight distribution (3000~8000 Da) to meet regional clinical efficacy requirements.